3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
350
Polycystic Ovary Syndrome
39
Endometrial Neoplasms
22
Neoplasm Metastasis
21
Ovarian Neoplasms
16
Infertility
12
Neoplasms
11
Fallopian Tube Neoplasms
8
Advanced Breast Cancer
8
Triple Negative Breast Neoplasms
7
Carcinoma, Intraductal, Noninfiltrating
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Recurrence
6
Osteoporosis
6
Carcinoma, Lobular
6
Breast Diseases
6
Breast Carcinoma In Situ
6
Prostatic Neoplasms
5
Leiomyoma
4
Infertility, Female
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Neoplasms, Hormone-Dependent
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Anovulation
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Interventions
Carboplatin
69
Paclitaxel
47
Radiotherapy
44
Pemetrexed
42
Cisplatin
41
Bevacizumab
36
Gemcitabine
27
Docetaxel
27
Erlotinib Hydrochloride
23
Gefitinib
18
pembrolizumab
14
Taxes
13
Vinorelbine
10
Cetuximab
10
Radiation
8
Nivolumab
8
Magnetic Resonance Spectroscopy
8
Radiosurgery
7
Platinum
7
Etoposide
7
Surgical Procedures, Operative
6
Radiotherapy, Conformal
6
ceritinib
5
capmatinib
5
aflutinib
5
Specimen Handling
5
Neoadjuvant Therapy
5
Mastectomy, Segmental
5
Cyclophosphamide
5
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma of Lung
×
Letrozole
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled